TrialThe oncologist2024

CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial.

Francesco Schettini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.